Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 3/20 | 0.93 |
| ▸ | MVD | P53602 | 2/20 | 0.42 |
| ▸ | FNTA | P49354 | 5/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.41 |
| ▸ | FNTB | P49356 | 3/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isopentenylpyrophosphate SCHEMBL125521 | 0.96 | BTN3A1 (1.00) | BTN3A1MVDFNTAPGGT1BFNTB | |
| Isopentenylpyrophosphate SCHEMBL15053699 | 0.96 | BTN3A1 (1.00) | BTN3A1MVDFNTAPGGT1BFNTB | |
| Isopentenylpyrophosphate SCHEMBL1363821 | 0.94 | BTN3A1 (0.96) | BTN3A1MVDFNTAPGGT1BFNTB | |
| Isopentenylpyrophosphate SCHEMBL4363351 | 0.94 | BTN3A1 (0.96) | BTN3A1MVDFNTAPGGT1BFNTB | |
| Isopentenylpyrophosphate SCHEMBL29787025 | 0.94 | BTN3A1 (0.96) | BTN3A1MVDFNTAPGGT1BFNTB | |
| Isopentenylpyrophosphate SCHEMBL2027470 | 0.94 | BTN3A1 (0.96) | BTN3A1MVDFNTAPGGT1BFNTB | |
| SCHEMBL3215369 | 0.94 | BTN3A1 (0.81) | BTN3A1MVDFNTAPGGT1BFNTB | |
| Isopentenylpyrophosphate SCHEMBL21571357 | 0.93 | BTN3A1 (0.93) | BTN3A1MVDFNTAPGGT1BFNTB | |
| SCHEMBL3211424 | 0.92 | BTN3A1 (0.85) | BTN3A1MVDFNTAPGGT1BFNTB | |
| Isopentenylpyrophosphate SCHEMBL21571270 | 0.89 | BTN3A1 (0.86) | BTN3A1MVDFNTAPGGT1BFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113710257-A | Methods of γ δ T cell homing and retention, optionally using natural killer cells, for generating cell compositions for therapy | 盖米达细胞有限公司 | 2021-11-26 | — | — | CN | disclosed |
| CN-111801349-A | Methods for selectively expanding 3 gamma T cell populations and compositions thereof | 阿迪塞特生物股份有限公司 | 2020-10-20 | — | — | CN | disclosed |
| US-10103401-B2 | Polymer electrolyte composition and polymer electrolyte membrane, polymer electrolyte membrane with catalyst layer, membrane electrode assembly, and polymer electrolyte fuel cell each using the same | TORAY INDUSTRIES, INC. (JP) | 2018-10-16 | — | — | US | disclosed |
| EP-3131145-B1 | POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, MEMBRANE-ELECTROLYTE ASSEMBLY, AND SOLID POLYMER FUEL CELL USING SAME | TORAY INDUSTRIES (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-20170125832-A1 | POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, POLYMER ELECTROLYTE MEMBRANE WITH CATALYST LAYER, MEMBRANE ELECTRODE ASSEMBLY, AND POLYMER ELECTROLYTE FUEL CELL EACH USING THE SAME | TORAY INDUSTRIES, INC. (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-3131145-A1 | POLYMER ELECTROLYTE COMPOSITION AND POLYMER ELECTROLYTE MEMBRANE, MEMBRANE-ELECTROLYTE ASSEMBLY, AND SOLID POLYMER FUEL CELL USING SAME | Toray Industries, Inc. (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-20100068179-A1 | Phosphohalohydrins, Process For The Production Thereof And Use Thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2010-03-18 | — | — | US | disclosed |
| US-7625879-B2 | Phosphohalohydrins, process for the production thereof and use thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2009-12-01 | — | — | US | disclosed |
| US-7432253-B2 | Phosphoepoxides, method for making same and uses | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2008-10-07 | — | — | US | disclosed |
| US-20060287281-A1 | Phosphohalohydrins, process for the production thereof and use thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2006-12-21 | — | — | US | disclosed |
| US-7109183-B2 | Phosphohalohydrins, process for the production thereof and use thereof | Institut National de la Sante et de la Recherchik Medicale (FR) | 2006-09-19 | — | — | US | disclosed |
| US-7101711-B1 | Phosphoepoxides, method for making same and uses | INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE (FR) | 2006-09-05 | — | — | US | disclosed |
| US-20040087555-A1 | Phosphohalohydrins, process for the production thereof and use thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICATE (FR) | 2004-05-06 | — | — | US | disclosed |
| US-6660723-B1 | Activating primate gamma delta lymphocytes | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2003-12-09 | — | — | US | disclosed |
| EP-1109818-B1 | PHOSPHOEPOXIDES, METHOD FOR MAKING SAME AND USES | INST NAT SANTE RECH MED (FR) | 2002-11-06 | — | — | EP | disclosed |
| EP-1109817-B1 | PHOSPHOHALOHYDRINS, METHOD FOR MAKING SAME AND USES | INST NAT SANTE RECH MED (FR) | 2002-06-05 | — | — | EP | disclosed |
| EP-1109818-A1 | PHOSPHOEPOXIDES, METHOD FOR MAKING SAME AND USES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2001-06-27 | — | — | EP | disclosed |
| EP-1109817-A1 | PHOSPHOHALOHYDRINS, METHOD FOR MAKING SAME AND USES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012519-A1 | PHOSPHOEPOXIDES, METHOD FOR MAKING SAME AND USES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012516-A1 | PHOSPHOHALOHYDRINS, METHOD FOR MAKING SAME AND USES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087555-A1 | Phosphohalohydrins, process for the production thereof and use thereof | CD4, HRH3, HRH1 | BTN3A1 24/4885MVD 2341/4885FNTA 4834/4885 |
| US-20060287281-A1 | Phosphohalohydrins, process for the production thereof and use thereof | CD4, CCR9, BCL9 | BTN3A1 15/4885MVD 1563/4885FNTA 4792/4885 |
| US-20100068179-A1 | Phosphohalohydrins, Process For The Production Thereof And Use Thereof | CD4, CCR9, ICOS | BTN3A1 16/4885MVD 1784/4885FNTA 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.